WO2026027990 - BIOACTIVE GROWTH FACTORS FOR DERMAL TOPICAL APPLICATIONS
National phase entry is expected:
Publication Number
WO/2026/027990
Publication Date
05.02.2026
International Application No.
PCT/IB2025/057112
International Filing Date
14.07.2025
Title **
[English]
BIOACTIVE GROWTH FACTORS FOR DERMAL TOPICAL APPLICATIONS
[French]
FACTEURS DE CROISSANCE BIOACTIFS POUR APPLICATIONS TOPIQUES DERMIQUES
Applicants **
CORE BIOGENESIS SAS
Inventors
REEBER, Alexandre
ABBOUD, Tony
NEY, Michel
WEHBI, Houssein
MEZIADI, Chouaib
Priority Data
63/677,107
30.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3184 | |
| EPO | Filing, Examination, Granting | 23812 | |
| Japan | Filing, Examination, Granting | 3019 | |
| South Korea | Filing, Examination, Granting | 3831 | |
| USA | Filing, Examination, Granting | 9340 |
Total:
43,186
Contact Us
Abstract[English]
Disclosed are novel formulations for dermal topical applications and methods for making the same. The formulations comprise oleosome-emulsified fibroblast growth factor 2 (FGF-2). The formulations may be used to treat skin conditions, including conditions associated with skin aging and skin injury.[French]
L'invention divulgue de nouvelles formulations destinées à des applications topiques dermiques et leurs procédés de production. Les formulations comprennent le facteur de croissance des fibroblastes émulsionné dans des oléosomes 2 (FGF-2). Les formulations peuvent être utilisées pour traiter des affections cutanées, y compris des états associés au vieillissement cutané et à une lésion cutanée.